tradingkey.logo

Surmodics Inc

SRDX
26.790USD
+0.370+1.40%
Close 11/07, 16:00ETQuotes delayed by 15 min
383.04MMarket Cap
LossP/E TTM

Surmodics Inc

26.790
+0.370+1.40%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Surmodics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Surmodics Inc's Score

Industry at a Glance

Industry Ranking
73 / 209
Overall Ranking
164 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Hold
Current Rating
43.000
Target Price
+47.26%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Surmodics Inc Highlights

StrengthsRisks
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.14% year-on-year.
Fairly Valued
The company’s latest PE is -21.65, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.05M shares, decreasing 21.65% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 7.92, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 29.57M, representing a year-over-year decrease of 2.55%, while its net profit experienced a year-over-year decrease of 29.60%.

Score

Industry at a Glance

Previous score
7.92
Change
0

Financials

7.77

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

6.35

Operational Efficiency

10.00

Growth Potential

8.11

Shareholder Returns

7.36

Surmodics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.02, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -21.65, which is -515.04% below the recent high of 89.87 and -1958.65% above the recent low of -445.76.

Score

Industry at a Glance

Previous score
7.02
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 73/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 6.00, which is lower than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Surmodics Inc is 43.00, with a high of 43.00 and a low of 43.00.

Score

Industry at a Glance

Previous score
6.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Hold
Current Rating
43.000
Target Price
+47.26%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Surmodics Inc
SRDX
2
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
32
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
30
1
2
3
...
22

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.59, which is lower than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 28.36 and the support level at 25.54, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.40
Change
0.19

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(4)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
0.167
Neutral
RSI(14)
36.321
Neutral
STOCH(KDJ)(9,3,3)
34.784
Neutral
ATR(14)
0.971
High Vlolatility
CCI(14)
-125.535
Sell
Williams %R
67.376
Sell
TRIX(12,20)
-0.369
Sell
StochRSI(14)
30.493
Neutral
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
27.315
Sell
MA10
27.293
Sell
MA20
27.571
Sell
MA50
29.788
Sell
MA100
31.529
Sell
MA200
30.988
Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 91.28%, representing a quarter-over-quarter increase of 3.25%. The largest institutional shareholder is The Vanguard, holding a total of 810.18K shares, representing 5.67% of shares outstanding, with 0.83% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
1.02M
-2.58%
AllianceBernstein L.P.
850.47K
+0.13%
The Vanguard Group, Inc.
Star Investors
810.18K
+1.44%
Soleus Capital Management, L.P.
789.06K
--
Gabelli Funds, LLC
745.83K
+3.73%
Trium Capital LLP
716.78K
--
UBS Financial Services, Inc.
422.72K
+543.00%
Hudson Bay Capital Management LP
400.00K
-13.97%
Qube Research & Technologies Ltd
393.98K
+1.23%
Readystate Asset Management LP
433.61K
--
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 6.30, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.39. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
6.30
Change
0
Beta vs S&P 500 index
1.38
VaR
+3.80%
240-Day Maximum Drawdown
+34.16%
240-Day Volatility
+40.03%

Return

Best Daily Return
60 days
+3.23%
120 days
+12.32%
5 years
+29.74%
Worst Daily Return
60 days
-5.06%
120 days
-5.06%
5 years
-29.35%
Sharpe Ratio
60 days
-5.48
120 days
-0.25
5 years
-0.02

Risk Assessment

Maximum Drawdown
240 days
+34.16%
3 years
+55.53%
5 years
+71.60%
Return-to-Drawdown Ratio
240 days
-0.93
3 years
-0.11
5 years
-0.11
Skewness
240 days
+0.31
3 years
+0.87
5 years
+0.74

Volatility

Realised Volatility
240 days
+40.03%
5 years
+50.07%
Standardised True Range
240 days
+3.85%
5 years
+5.00%
Downside Risk-Adjusted Return
120 days
-46.84%
240 days
-46.84%
Maximum Daily Upside Volatility
60 days
+18.32%
Maximum Daily Downside Volatility
60 days
+25.89%

Liquidity

Average Turnover Rate
60 days
+1.39%
120 days
+1.03%
5 years
--
Turnover Deviation
20 days
+61.96%
60 days
+2.37%
120 days
-23.87%

Peer Comparison

Healthcare Equipment & Supplies
Surmodics Inc
Surmodics Inc
SRDX
7.18 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI